Expert Reports Regarding These Cancer Types Will Be Given In Zantac MDL
A disclosure filed on January 8 revealed what types of cancer expert reports will cover in the ongoing Zantac cancer multidistrict litigation.
The disclosure stated that the plaintiffs’ leadership intends to provide expert reports regarding the following types of cancer which they will argue are linked to Zantac:
- Bladder cancer
- Breast cancer
- Colorectal/intestinal cancer
- Esophageal cancer
- Gastric cancer
- Kidney cancer
- Liver cancer
- Lung cancer
- Pancreatic cancer
- Prostate cancer
The court will consider arguments and briefings regarding the reports once they are filed. The arguments and briefings from both sides will debate whether the expert reports are based on sound science and are reliable enough under the Daubert standard for individual cases to proceed in front of juries.
“Hundreds of thousands” of people have developed cancer due to Zantac (ranitidine) use, according to the MDL’s master complaint. Recent studies demonstrate that consumers who take Zantac are exposed to “staggering amounts” of a “potent human carcinogen,” NDMA, according to the complaint.
A single Zantac pill can contain “hundreds of times” the allowable limit of NDMA, according to the complaint, which claims that NDMA is generated as Zantac:
- Breaks down in peoples’ digestive systems;
- Interacts with human enzymes;
- Reacts to itself in normal storage conditions, with this reaction speeding up as it gets hotter, and/or;
- Is made.
The central claim of the master complaint is that the defendants knew or should have known that Zantac could cause cancer, yet failed to warn about this risk on the product’s labeling, in the marketing of the product, etc. The complaint claims that the defendants chose not to warn the public about the cancer risk due to the “temptation” of “maximizing the profits of an incredibly lucrative, government-conferred monopoly.”
The master complaint names Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Sanofi as brand-name defendants.
The master complaint notes that a 1979 news article stated NDMA had caused cancer in almost every lab animal tested, that the IARC classifies NDMA as a “probable human carcinogen,” that the FDA said NDMA “could cause cancer” in people, that the WHO stated there is “conclusive evidence that NDMA is a potent carcinogen,” and that a 1995 study found that those exposed to over 0.51 ng/day of NDMA saw a 700 percent increase in their risk of developing gastric cancer.
The FDA requested that all drugs containing ranitidine be removed from the U.S. market in April 2020. The request came after testing lab Valisure found NDMA in ranitidine pills and filed a citizen petition requesting the recall of all products containing ranitidine.